To study the benefits of addition of Cabergoline to Metformin in women with PCOS
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: E282- Polycystic ovarian syndromeHealth Condition 2: E282- Polycystic ovarian syndrome
- Registration Number
- CTRI/2024/08/071776
- Lead Sponsor
- il
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Women diagnosed with PCOS by Rotterdam
criteria, Age 16-35 years, BMI 23-35 kg/m2, Willing to participate in the study
Exclusion Criteria
Patients with other endocrine disorders such as
Cushing’s Syndrome, acromegaly, pituitary
adenoma, etc , Women planning pregnancy in next 6 months, Intolerability to cabergoline, Not willing to participate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Regularization of mensesTimepoint: 6 months
- Secondary Outcome Measures
Name Time Method Improvement in glycemic parameterTimepoint: 1, 3, 6 MONTHS;Reduction in serum inflammatory markersTimepoint: 1, 3, 6 months